prikaz prve stranice dokumenta A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes
  Download
PDF 681.63 KB
Scientific paper - Review paper
A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes
Diabetology, 4 (2023), 4; 440-452. https://doi.org/10.3390/diabetology4040038
Gkrinia, Elvira Meni Maria; Faour, Andrea Katrin; Belančić, Andrej; Bazile, Jacques; Marland, Emma; Vitezić, Dinko

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Gkrinia, E. M. M., Faour, A. K., Belančić, A., Bazile, J., Marland, E. & Vitezić, D. (2023). A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes. Diabetology, 4. (4), 440-452. doi: 10.3390/diabetology4040038

Gkrinia, Elvira Meni Maria, et al. "A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes." Diabetology, vol. 4, no. 4, 2023, pp. 440-452. https://doi.org/10.3390/diabetology4040038

Gkrinia, Elvira Meni Maria, Andrea Katrin Faour, Andrej Belančić, Jacques Bazile, Emma Marland and Dinko Vitezić. "A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes." Diabetology 4, no. 4 (2023): 440-452. https://doi.org/10.3390/diabetology4040038

Gkrinia, E. M. M., et al. (2023) 'A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes', Diabetology, 4(4), pp. 440-452. doi: 10.3390/diabetology4040038

Gkrinia EMM, Faour AK, Belančić A, Bazile J, Marland E, Vitezić D. A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes. Diabetology [Internet]. 2023 October 13 [cited 2024 November 09];4(4):440-452. doi: 10.3390/diabetology4040038

E. M. M. Gkrinia, A. K. Faour, A. Belančić, J. Bazile, E. Marland and D. Vitezić, "A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes", Diabetology, vol. 4, no. 4, pp. 440-452, October 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:379724. [Accessed: 09 November 2024]

Metadata
Title (english)A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes
AuthorElvira Meni Maria Gkrinia
AuthorAndrea Katrin Faour
AuthorAndrej Belančić
AuthorJacques Bazile
AuthorEmma Marland
AuthorDinko Vitezić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Clinical Pharmacology and Toxicology
Abstract (english)
Diabetes is a chronic, metabolic disease characterized by hyperglycemia, which occurs as a result of inadequate production or utilization of insulin. Type 2 diabetes (T2D) is the most common type of diabetes with estimates projecting a prevalence of more than 1 billion people living with T2DM by 2050. Hence, it was decided to conduct a systematic literature review of health economic evaluations of insulin, the most common medication used for the treatment of the disease, to inform policy. Pharmacoeconomic analyses, written in English and published after 2016, were considered for inclusion. PubMed/Medline, Global Health, Embase and Health Management Consortium were searched separately between 5 July 2023 and 17 July 2023. Grey literature articles were searched on ISPOR and the Cost-Effectiveness Analysis Registry during the same period. After the exclusion criteria were applied, 21 studies were included. Using the BMJ checklist, a quality appraisal was performed on all included studies. Data extraction was performed manually. Regarding evidence synthesis, data were heterogenous and are presented based on study type. The results showed a variety of treatment combinations being available for the treatment of diabetes, with insulin degludec/DegLira and semaglutide being cost-effective despite their high cost, due to the effectiveness of managing the disease. Research around the cost-effectiveness or cost-utility of insulin has potential to progress further, to ensure informed policy-making in the future.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleDiabetology
Numberingvol. 4, no. 4, pp. 440-452
e-ISSN2673-4540
DOIhttps://doi.org/10.3390/diabetology4040038
URN:NBNurn:nbn:hr:184:379724
Publication2023-10-13
Document URLhttps://www.mdpi.com/2673-4540/4/4/38
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-10-18 10:23:26